Salih Kilic1, Mutlu Çagan Sümerkan2, Volkan Emren3, Lütfü Bekar4, Sinan Cersit5, Elif Tunc6, Gülay Gök7, Emine Altuntas8, Uğur Canpolat9, Umit Yasar Sinan10, Namık Özmen11, Mehdi Zoghi12. 1. Department of Cardiology, Ege University Faculty of Medicine, Izmir, Turkey. kilicsalihhh@gmail.com. 2. Department of Cardiology, Sisli Hamidiye Etfal Education and Research Hospital, Istanbul, Turkey. 3. Department of Cardiology, Afyonkarahisar State Hospital, Afyon, Turkey. 4. Department of Cardiology, Hitit University Corum Education and Research Hospital, Corum, Turkey. 5. Department of Cardiology, Kosuyolu Kartal Heart Training and Research Hospital, Istanbul, Turkey. 6. Department of Cardiology, Izmir Military Hospital, İzmir, Turkey. 7. Department of Cardiology, Mardin State Hospital, Mardin, Turkey. 8. Department of Cardiology, Bingol State Hospital, Bingol, Turkey. 9. Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey. 10. Department of Cardiology, Cardiology Institute of İstanbul University, Istanbul, Turkey. 11. Department of Cardiology, GATA Haydarpaşa Training Hospital, Istanbul, Turkey. 12. Department of Cardiology, Ege University Faculty of Medicine, Izmir, Turkey.
Abstract
BACKGROUND: Secondary prevention plays an important role after acute coronary event due to high risk of adverse events in elderly. In present study we aimed to evaluate the lifestyle, management of risk factors and medical treatment for secondary protection in elderly patients with known coronary heart disease (CHD). METHODS: ELDERTURK is a non-interventional, multi-centered, observational study, which included total of 5694 elderly patients ( > 65 years) from 50 centers in Turkey. In this study elderly patients from the ELDERTURK population with known CHD were evaluated for cardiovascular risk factors, comor- bidities and medication usage. RESULTS: A total of 2976 (52.3% of study) out of 5694 patients included in the ELDERTURK study were evaluated. All had known CHD with a mean age of 73.4 ± 6.2 years and 60.3% were male. 13.0% of patients were smokers, 42.4% were overweight and 21.1% were obese. Only 23.6% of patients reported to do regular exercise, 73.4% had history of hypertension, 47.4% had dyslipidemia and 33.9% had diabetes mellitus. The rate of patients with systolic blood pressure > 140 mmHg were 31.1% and only 13.9% of patients had a recommended ≤ 70 mg/dL level of low-density lipoprotein cholesterol. Anti- platelet, statin, beta-blocker and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker usage was limited to 27.3%. CONCLUSIONS: The ELDERTURK study shows that many patients with CHD have a high prevalence of modifiable risk factors and unhealthy lifestyle. Apart from this, many patients are not receiving thera- peutic intervention and as a consequence most were not achieving the recommended goals.
BACKGROUND: Secondary prevention plays an important role after acute coronary event due to high risk of adverse events in elderly. In present study we aimed to evaluate the lifestyle, management of risk factors and medical treatment for secondary protection in elderly patients with known coronary heart disease (CHD). METHODS: ELDERTURK is a non-interventional, multi-centered, observational study, which included total of 5694 elderly patients ( > 65 years) from 50 centers in Turkey. In this study elderly patients from the ELDERTURK population with known CHD were evaluated for cardiovascular risk factors, comor- bidities and medication usage. RESULTS: A total of 2976 (52.3% of study) out of 5694 patients included in the ELDERTURK study were evaluated. All had known CHD with a mean age of 73.4 ± 6.2 years and 60.3% were male. 13.0% of patients were smokers, 42.4% were overweight and 21.1% were obese. Only 23.6% of patients reported to do regular exercise, 73.4% had history of hypertension, 47.4% had dyslipidemia and 33.9% had diabetes mellitus. The rate of patients with systolic blood pressure > 140 mmHg were 31.1% and only 13.9% of patients had a recommended ≤ 70 mg/dL level of low-density lipoprotein cholesterol. Anti- platelet, statin, beta-blocker and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker usage was limited to 27.3%. CONCLUSIONS: The ELDERTURK study shows that many patients with CHD have a high prevalence of modifiable risk factors and unhealthy lifestyle. Apart from this, many patients are not receiving thera- peutic intervention and as a consequence most were not achieving the recommended goals.
Authors: Mark A Williams; Jerome L Fleg; Philip A Ades; Bernard R Chaitman; Nancy Houston Miller; Syed M Mohiuddin; Ira S Ockene; C Barr Taylor; Nanette K Wenger Journal: Circulation Date: 2002-04-09 Impact factor: 29.690
Authors: Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner Journal: Circulation Date: 2011-12-15 Impact factor: 29.690
Authors: Wilbert S Aronow; Jerome L Fleg; Carl J Pepine; Nancy T Artinian; George Bakris; Alan S Brown; Keith C Ferdinand; Mary Ann Forciea; William H Frishman; Cheryl Jaigobin; John B Kostis; Giuseppi Mancia; Suzanne Oparil; Eduardo Ortiz; Efrain Reisin; Michael W Rich; Douglas D Schocken; Michael A Weber; Deborah J Wesley Journal: J Am Coll Cardiol Date: 2011-04-26 Impact factor: 24.094
Authors: Sarah Lewington; Gary Whitlock; Robert Clarke; Paul Sherliker; Jonathan Emberson; Jim Halsey; Nawab Qizilbash; Richard Peto; Rory Collins Journal: Lancet Date: 2007-12-01 Impact factor: 79.321
Authors: Karen P Alexander; L Kristin Newby; Christopher P Cannon; Paul W Armstrong; W Brian Gibler; Michael W Rich; Frans Van de Werf; Harvey D White; W Douglas Weaver; Mary D Naylor; Joel M Gore; Harlan M Krumholz; E Magnus Ohman Journal: Circulation Date: 2007-05-15 Impact factor: 29.690
Authors: Ahmet Çelik; Servet İzci; Mehmet Ali Kobat; Ahmet Hakan Ateş; Abdülkadir Çakmak; Yasin Çakıllı; Mehmet Birhan Yılmaz; Mehdi Zoghi Journal: Anatol J Cardiol Date: 2015-11-19 Impact factor: 1.596
Authors: Piotr Jankowski; Dariusz A Kosior; Paweł Sowa; Karolina Szóstak-Janiak; Paweł Kozieł; Agnieszka Krzykwa; Emilia Sawicka; Maciej Haberka; Małgorzata Setny; Karol Kamiński; Zbigniew Gąsior; Aldona Kubica; Dirk De Bacquer; Guy De Backer; Kornelia Kotseva; David Wood; Andrzej Pająk; Danuta Czarnecka Journal: Cardiol J Date: 2020-05-21 Impact factor: 2.737